ALK and neoplasm: This was supported by ex vivo experiments with patient-derived tumor cells carrying the ALK-ST2 and -ST3 variants and with isogenic MCF10A cells, both of which were sensitive to ceritinib and crizotinib but not or to a much lesser extent to alectinib.